Table 2.

Participant Demographics in the Testing Phase

	Male			Female
	Patients (N = 30)	Controls (N = 30)	P value	Patients (N = 30)	Controls (N = 30)	P value
Age (years)	29.17 ± 5.78	28.66 ± 6.10	0.336a	29.54 ± 5.77	29.58 ± 5.63	0.653a
Education (years)	14.15 ± 2.23	15.82 ± 3.16	0.063a	14.37 ± 2.51	15.76 ± 2.86	0.127a
PANSS‐positive subscale score	13.13 ± 5.67			13.72 ± 5.45		0.918b
PANSS‐negative subscale score	15.21 ± 5.35			16.20 ± 6.16		0.121b
PANSS general psychopathology subscale score	26.63 ± 8.72			25.52 ± 8.14		0.631b
Duration of illness (years)	8.86 ± 5.22			7.72 ± 5.19		0.375b
Age of onset (years)	22.94 ± 7.05			23.11 ± 6.93		0.452b
Total antipsychotic dose (mg)c	303.45 ± 195.92			293.77 ± 177.68		0.926b

^aThe P value between patients and controls.

^bThe P value between male and female patients.

^cDaily chlorpromazine equivalent dose.